Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 3, 2014, Pages 458-469

  Assi, Hikmat H ^a,b   Paran, Chris ^a   VanderVeen, Nathan ^a   Savakus, Jonathan ^a   Doherty, Robert ^a   Petruzzella, Emanuele ^c   Hoeschele, James D ^c   Appelman, Henry ^a   Raptis, Leda ^d   Mikkelsen, Tom ^e   Lowenstein, Pedro R ^a   Castro, Maria G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EASTERN MICHIGAN UNIVERSITY   (United States)

^d QUEEN S UNIVERSITY   (Canada)

^e HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 BROMOPYRIDIN 2 YL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; 4 BENZYL 1 [THIENO(2,3 D)PYRIMIDIN 4 YL]PIPERIDINE; ANTINEOPLASTIC AGENT; CPA 7; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ML 116; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRICHLORONITRITODIAMMINEPLATINUM; UNCLASSIFIED DRUG; WP 1066;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG EFFICACY; EMBRYO; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHLORINE COMPOUNDS; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOMA; HEK293 CELLS; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; MELANOMA, EXPERIMENTAL; MICE; PIPERIDINES; PLATINUM COMPOUNDS; PYRIDINES; SMALL MOLECULE LIBRARIES; STAT3 TRANSCRIPTION FACTOR; TISSUE DISTRIBUTION; TYRPHOSTINS;

EID: 84901228091     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214619     Document Type: Article

References (50)

1. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R et al. (2008) The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14:8228-8235.
2. Al Zaid Siddiquee K and Turkson J (2008) STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18:254-267.
3. Assi H, Candolfi M, Lowenstein P, and Castro M (2013) Rodent glioma models: in-tracranial stereotactic allografts and xenografts, in Animal Models of Brain Tumors (Martínez Murillo R and Martinez A eds) vol 77, pp 229-243, Humana Press, New York.
4. Ausman JI, Shapiro WR, and Rall DP (1970) Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 30: 2394-2400.
5. Avdeef A (2005) The rise of PAMPA. Expert Opin Drug Metab Toxicol 1:325-342.
6. Boulikas T and Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level (review). Oncol Rep 10:1663-1682.
7. Brantley EC and Benveniste EN (2008) Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6:675-684.
8. Bromberg JF, Horvath CM, Besser D, Lathem WW, and Darnell JE, Jr (1998) Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18: 2553-2558.
9. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, and Moore PF, et al. (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85:133-148.
10. Chen T, Wang LH, and Farrar WL (2000) Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60: 2132-2135.
11. Collins FS and Tabak LA (2014) Policy: NIH plans to enhance reproducibility. Nature 505:612-613.
12. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, and Liu C, et al. (2009) HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 6:e10.
13. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, and Karras J, et al. (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107:351-362.
14. Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nat New Biol 242:148-149.
15. Gormley PE, Gangji D, Wood JH, and Poplack DG (1981) Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 5:257-260.
16. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12:11-19.
17. Groner B, Lucks P, and Borghouts C (2008) The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 19:341-350.
18. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, and Heimberger AB (2012) The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 131:8-17.
19. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, and Heimberger AB (2007) A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67:9630-9636.
20. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, and Sawaya R, et al. (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26: 2435-2444.
21. Kharbanda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, Bharti A, Yuan ZM, Saxena S, and Weichselbaum R, et al. (1997) Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 94:6939-6942.
22. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ et al. (2008) A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14: 5759-5768.
23. Kumar S, Arbab AS, Jain R, Kim J, deCarvalho AC, Shankar A, Mikkelsen T, and Brown SL (2012) Development of a novel animal model to differentiate radiation necrosis from tumor recurrence. J Neurooncol 108:411-420.
24. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, and Kulp S, et al. (2010) Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 70:2445-2454.
25. Littlefield SL, Baird MC, Anagnostopoulou A, and Raptis L (2008) Synthesis, characterization and Stat3 inhibitory properties of the prototypical platinum(IV) anticancer drug, [PtCl3(NO2)(NH3)2] (CPA-7). Inorg Chem 47:2798-2804.
26. Madoux F, Koenig M, Sessions H, Nelson E, Mercer BA, Cameron M, Roush W, Frank D, and Hodder P (2010) Modulators of STAT Transcription Factors for the Targeted Therapy of Cancer (STAT3 Inhibitors), Probe Reports from the NIH Molecular Libraries Program, Bethesda, MD.
27. Martic-Kehl MI, Schibli R, and Schubiger PA (2012) Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur J Nucl Med Mol Imaging 39:1492-1496.
28. Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G, and Leonard WJ (1995) Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269:79-81.
29. Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS et al. (2011) STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 17:1452-1462.
30. Nakagawa H, Miyawaki Y, Tokiyoshi K, Tsuruzono K, Yamada M, Kanayama T, and Hayakawa T (1994) [Pharmacokinetics of plasma and cerebrospinal fluid cis-platin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin]. No Shinkei Geka 22:35-42.
31. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, and Yu H (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21:7001-7010.
32. Plimack ER, Lorusso PM, McCoon P, Tang W, Krebs AD, Curt G, and Eckhardt SG (2013) AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 18:819-820.
33. Prinz F, Schlange T, and Asadullah K (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10:712.
34. Raz A and Hart IR (1980) Murine melanoma: a model for intracranial metastasis. Br J Cancer 42:331-341.
35. Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, and Bigner DD (1997) Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41:1365-1372; discussion 1372-1373.
36. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, and Hennessy L, et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110:3507-3512.
37. Srinivasan D, Sims JT, and Plattner R (2008) Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 27:1095-1105.
38. Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, and Weiss S (2013) On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro-oncol 15:198-207.
39. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, and Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315-5320.
40. Turkson J and Jove R (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19:6613-6626.
41. Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, and Jove R (2004) Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3:1533-1542.
42. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, and Macleod MR (2010) Can animal models of disease reliably inform human studies? PLoS Med 7:e1000245.
43. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, and Coppola D, et al. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48-54.
44. Wei CC, Ball S, Lin L, Liu A, Fuchs JR, Li PK, Li C, and Lin J (2011) Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells. Int J Oncol 38:279-285.
45. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, and Chen MY, et al. (2008) Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 7:3519-3526.
46. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, and Jove R (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269:81-83.
47. Yu H, Kortylewski M, and Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51.
48. Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, and Badie B (2009) Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 57:1458-1467.
49. Zhong Z, Wen Z, and Darnell JE, Jr (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95-98.
50. Zhou T, Georgeon S, Moser R, Moore DJ, Caflisch A, and Hantschel O (2014) Specificity and mechanism-of-Action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia 28:404-407.